Tumor immunotherapy, particularly immune checkpoint inhibitors (ICBs), has transformed cancer treatment by activating T-cells, reversing CD8 T-cell depletion, and stimulating immune cells to recognize and eliminate tumor cells. Here, CD8A is linked to neoplasm.